發(fā)布時間：2018-04-25 07:19

  本文選題：富含亮氨酸重復(fù)序列G蛋白偶聯(lián)受體 + 子宮內(nèi)膜癌　； 參考：《實用婦產(chǎn)科雜志》2017年02期

【摘要】：目的:探討富含亮氨酸重復(fù)序列G蛋白偶聯(lián)受體5(LGR5)在子宮內(nèi)膜癌中的表達(dá)情況及其與臨床病理因素的關(guān)系。方法:采用免疫組織化學(xué)SABC法檢測90例子宮內(nèi)膜癌及30例正常子宮內(nèi)膜組織中LGR5表達(dá)情況,并分析其與臨床病理因素的關(guān)系。結(jié)果:LGR5在子宮內(nèi)膜癌組織中的陽性表達(dá)率(63.3%)顯著高于正常子宮內(nèi)膜(23.3%)(P0.001)。LGR5在1/2肌層浸潤組的陽性表達(dá)率(72.5%)顯著高于≥1/2肌層浸潤組(33.3%)(P=0.001)。LGR5的陽性表達(dá)率在年齡、病理類型、組織學(xué)分級、宮頸累及、淋巴結(jié)轉(zhuǎn)移、FIGO分期組間差異均無統(tǒng)計學(xué)意義(P0.05)。多因素分析發(fā)現(xiàn)LGR5是子宮內(nèi)膜癌有無肌層浸潤的獨立影響因素(OR=0.163,95%CI 0.034~0.772,P=0.022)。結(jié)論:LGR5在子宮內(nèi)膜癌組織中表達(dá)上調(diào),提示與肌層浸潤深度相關(guān),可能在子宮內(nèi)膜癌的發(fā)生中起一定作用。
[Abstract]:Objective: to investigate the expression of Leucine-rich repeat G protein coupled receptor 5 LGR5 in endometrial carcinoma and its relationship with clinicopathological factors. Methods: immunohistochemical SABC method was used to detect the expression of LGR5 in 90 cases of endometrial carcinoma and 30 cases of normal endometrium, and the relationship between the expression of LGR5 and clinicopathological factors was analyzed. Results the positive expression rate of 10% LGR5 in endometrial carcinoma (63.3%) was significantly higher than that in normal endometrium (23.3%). The positive expression rate of LGR5 in 1 / 2 myometrium infiltrating group was significantly higher than that in 鈮，

本文編號：1800335